ThromboGenics to present a preclinical overview of its two most...

ThromboGenics NV , a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland. The presentations will provide an overview of the extensive preclinical evidence supporting the potential benefits of its two promising